Torrent Pharmaceuticals on Sunday announced the acquisition of a controlling stake in JB Chemicals & Pharmaceuticals from KKR for ₹19,480 crore, translating into an equity valuation of ₹25,689 crore. The acquisition will be followed by a merger of JB Chemicals with Torrent Pharmaceuticals, a joint statement said. The Ahmedabad-based flagship company of the Torrent Group stated that the transaction will be executed in two phases. The acquisition of 46.39 per cent equity stake (on a fully diluted basis) through a Share Purchase Agreement at a consideration of ₹11,917 crore (₹1,600 per share) followed by a mandatory open offer to acquire up to 26 per cent of JB Pharma shares from public shareholders at an open offer price of ₹1,639.18 per share, the company stated in an official release. In addition to the above, Torrent has also expressed its intent to acquire up to 2.80 per cent of equity shares from certain employees of JB Pharma at the same price per share as KKR.

Alembic Pharmaceuticals Limited (Alembic) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma and Multiple Myeloma

The US FDA has completed a Pre-Approval Inspection (PAI) for a first to file controlled substance ANDA at the facility of Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of Granules India in Chantilly, Virginia, USA from June 23 to June 27 with one(1) 483 observation. Granules Pharmaceuticals, Inc. addressed and resolved the observation during the inspection.

The US FDA has issued an Establishment Inspection Report (EIR) against the Inspection conducted at its Neuland Laboratories’ Unit 2 manufacturing facility, at Sangareddy, from April 28 to May 2.

Published on June 30, 2025